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Reply to the Editor:
In contrast to the studies quoted by Misawa
and Fuse, our investigation was aimed at
comparing the effect of normothermic ver-
sus hypothermic cardiopulmonary bypass
(CPB) on postoperative hemostasis and in-
flammatory activation. For this purpose,
patients were randomly assigned to one of
the two CPB temperatures (37°C vs 28°C),
and several inflammatory and coagulative
markers were evaluated at different time
intervals in the postoperative period. We
found no difference between the two
groups and concluded that, at least for our
CPB times, CPB temperature has no effect
on postoperative hemostasis and inflamma-
tory activation.
However, we congratulate Misawa and
Fuse for their interesting studies on the
effects of normothermic CPB on platelet
function and cytokine production and we
applaud their efforts to clarify the systemic
effects of normothermia.
Mario Gaudino, MD
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An economic evaluation of lung
transplantation
To the Editor:
In the March 2002 issue of this Journal,
Anyanwu and associates1 reported a prospec-
tive multicenter study about cost-effective-
ness and cost-utility for the different types of
lung transplantation. Although the study is an
important addition to the existing literature,
the method by which survival gain was cal-
culated and the impact on their sensitivity
analyses should be discussed further.
First, in the presented study Anyanwu and
associates1 calculated survival for the first 4
years from actual data and from years 4 to 15
by using a parametric Weibull model, in ac-
cordance with a previous analysis by our
group.2 At 15 years, the survival curve after
transplantation was cut off despite a survival
of at least 25%, depending on the type of
transplantation. Survival on the waiting list
declined to 0% after 11 years. For a valid
comparison of costs and effects of both con-
ditions from a lifetime perspective, a survival
curve after transplantation should be con-
structed with further extrapolation until a sur-
vival of 0%.3,4 Therefore the survival after
lung transplantation in the presented study
was underestimated, because prolonged sur-
vival beyond 15 years was neglected. A
rough calculation indicates that extrapolation
to 0% survival would amount to an estimated
additional survival gain after transplantation
of 2 years. This is why, in contrast to others,5
Anyanwu and colleagues1 did not find sur-
vival as a principal determinant of cost-effec-
tiveness in their sensitivity analyses.
Second, the survival curve for the wait-
ing list, to which the survival after lung
transplantation was compared, was not
constructed in accordance with previously
reported methods.3,4 In previous studies the
transplantation date was chosen as the
starting point for this comparison, because
it would be unrealistic to assume that dif-
ferences in survival occur before transplan-
tation. For the situation on the waiting list,
no real transplantation date exists, and a
fictitious transplantation moment should be
created (Figure 1). This moment should be
based on the average stay of patients on the
waiting list before transplantation (about
12 months in the study by Anyanwu and
associates1). However, day 0 was used as
the starting point for the waiting list. Ap-
plied to our own data, these two methods
result in a difference in the cumulative
number of life years on the waiting list of
0.5 years (17%).
Obviously, changing the method for the
calculation of survival gain will also influ-
ence the number of quality-adjusted life years
gained. It is possible that this would affect the
results of the sensitivity analyses with respect
Figure 1. Actual waiting list survival, fictitious waiting list survival, and survival after
lung transplantation (LTx) in Groningen lung transplant program, 1990 through 1995.
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